Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.31
+0.57003.21%
Post-market: 18.310.00000.00%16:10 EDT
Volume:26.07K
Turnover:476.69K
Market Cap:108.03M
PE:- -
High:18.36
Open:18.30
Low:18.11
Close:17.74
52wk High:21.50
52wk Low:14.38
Shares:5.90M
Float Shares:5.90M
Volume Ratio:0.47
T/O Rate:0.44%
Dividend:0.71
Dividend Rate:3.90%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Wuxi Biologics (Cayman) Stock Slides 1.4% in Hong Kong

Dow Jones
·
Sep 07

UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts

Stock News
·
Sep 07

Hong Kong Stock Connect Biotech Surges: Dual-Antibody Outperforms Keytruda, Sector Heats Up

Deep News
·
Sep 06

Loose Fed Bets and AI Monetization Fuel Hong Kong Stocks Rally

Stock News
·
Sep 04

WuXi Bio Issues 3.2 Million Shares Following Option Exercise

Stock News
·
Sep 04

Wall Street Cues, Easing Bond Yields Boost Asian Stock Markets

MT Newswires Live
·
Sep 04

Daiwa Highlights AKESO's HARMONi-2 Milestone, Bolstering Case for Global NSCLC Study Success

Stock News
·
Sep 04

Brokerage Adds Tencent and Innovent Bio to Buy List While Maintaining Positive Outlook on Tech and Hardware Sectors

Stock News
·
Sep 04

WuXi Biologics Files HKEX Next-Day Disclosure Return, Share Capital Rises by 2,423,900 Shares

Reuters
·
Sep 03

Wuxi Biologics (Cayman) Stock Advances 3.0% in Hong Kong

Dow Jones
·
Sep 03

CSPC Pharmaceutical Group Stock Climbs 4.8% in Hong Kong

Dow Jones
·
Sep 03

Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support

Deep News
·
Sep 03

Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study

THOMSON REUTERS
·
Sep 03

Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial

Reuters
·
Sep 03

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc

THOMSON REUTERS
·
Sep 03

Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab

THOMSON REUTERS
·
Sep 03

WuXi Biologics Files HKEX Next-Day Disclosure Return Reporting 1,527,500 New Shares Issued Via Option Exercises

Reuters
·
Sep 02

CSPC Pharmaceutical Initiates Phase I Clinical Trial of Syh2056 Tablets in China

Reuters
·
Sep 01

Innovent Biologics Grants 583,731 Restricted Shares Under 2024 Share Scheme

Reuters
·
Sep 01

Innovent Biologics Files List of Board, Board Committee Members with Disclosure Duties

Reuters
·
Sep 01